Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:sec><jats:title>Background</jats:title><jats:p>Antibodies against glycine receptors (GlyR Ab) have been strongly linked to progressive encephalomyelitis with rigidity and myoclonus (PERM). Their association with other neurological disorders is poorly understood.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We looked retrospectively at all patients who were tested for (GlyR Abs) in the Walton Centre between 2010–2014.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>138 patients were tested. The pre-test diagnoses (n) were transverse myelitis (34), NMO (22, (7 AQP4 IgG+ve and 15 AQP4 IgG-ve), optic neuritis (17), MS (22), ADEM (4), other atypical demyelination (4), encephalitis (11), epilepsy (4), dementia (4), parkinsonism (3), functional disorders (3) and others (10). 53.6% (74) had a relapsing course</jats:p><jats:p>6/138 (4%) were positive for GlyR Ab. The diagnoses (n) were optic neuritis (2) one of which was AQP4 IgG+ve, NMO-AQP4-IgG negative (1), transverse myelitis (1), tumefactive demyelination (1) and undiagnosed spastic ataxic syndrome with normal imaging (1). 5/6 had a relapsing course and are on immunosuppressants.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Antibodies against GlyR are not common and seem to be associated with some non-PERM inflammatory CNS diseases, with a relapsing course. Larger studies are required to understand the clinical and prognostic significance of these early findings.</jats:p></jats:sec>

Original publication

DOI

10.1136/jnnp-2015-312379.130

Type

Conference paper

Publisher

BMJ

Publication Date

11/2015

Volume

86

Pages

e4.36 - e4